Reasons for discontinuation of telaprevir and incidence of the most common AEs and Grade 3–4 AEs during the telaprevir phase in the intent-to-treat population.

* Includes six F0–F2 patients.† Listed are drug-related AEs that occurred in at least 5% of the overall population during the telaprevir phase.‡ Included in this category are all related events that were described with a variety of descriptive terms.§ Listed are grade 3–4 drug-related AEs that occurred in at least 1% of the overall population during the telaprevir phase.¶ Listed are discontinuations that occurred in at least 5 patients. These figures are the number of patients who discontinued telaprevir; patients may have continued treatment with pegylated interferon plus ribavirin.AE, adverse event.Reasons for discontinuation of telaprevir and incidence of the most common AEs and Grade 3–4 AEs during the telaprevir phase in the intent-to-treat population.